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Summary 
 
The brindled mouse is an accurate model of the fatal human X-linked copper 
deficiency disorder, Menkes disease.  Males carrying the mutant allele of the Menkes gene 
orthologue Atp7a die in the second week of life.  To determine whether the genetic defect 
in the brindled mice could be corrected by expression of the human Menkes gene, male 
transgenic mice expressing ATP7A from the chicken β-actin composite promoter (CAG) 
were mated with female carriers of the brindled mutation (Atp7aMo-br).  Mutant males 
carrying the transgene survived, and were fertile but the copper defect was not completely 
corrected.  Unexpectedly males corrected with one transgenic line (T25#5) were mottled 
and resembled carrier females, this effect appeared to be caused by mosaic expression of 
the transgene.  In contrast males corrected with another line (T22#2) had agouti coats.   
Copper concentrations in tissues of the rescued mutants also resembled those of the 
heterozygous females, with high levels in kidney (84.6 ± 4.9 µg/g in corrected males v 
137.0 ± 44.3 µg/g in heterozygotes) and small intestine (15.6 ± 2.5 µg/g in corrected males 
v 15.7 ± 2.8 µg/g in heterozygotes).  The results show that the Menkes defect in mice is 
corrected by the human Menkes gene and that adequate correction is obtained even when 
the transgene expression does not match that of the endogenous gene. 
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1.  Introduction 
 
The mottled mice are an allelic series of mouse mutants that are due to mutations in 
the murine orthologue of the X-linked Menkes genes (Atp7a) [1, 2].  The mutant males 
exhibit a wide range of phenotypes ranging from prenatal lethality to mild symptoms such 
as a grey coat [3].  The carrier females are readily identified because they have a mottled 
coat due to the random X-inactivation while the unaffected mice have an agouti coat [4].  
As with the human disorder Menkes disease, the various defects in the mice are 
attributable to copper deficiency affecting a range of copper-dependent enzymes [5].  The 
affected gene encodes a copper transporting ATPase (Atp7a), which supplies copper to 
secreted cuproenzymes and also effluxes copper from the cell [6].  This copper transporter 
has an important role in transporting copper across the placenta, and mutant fetuses are 
severely copper deficient as a result, but the placenta accumulates copper [7].  The closest 
mottled mutant to Menkes disease is the brindled mouse, mutant males carrying the 
brindled allele Atp7aMo-br survive until about 15 days after birth, and have a markedly 
hypopigmented coat and curly whiskers due to copper deficiency [4].  The mutation in 
Atp7a in the brindled mouse was found to be an in-frame deletion of 6 nucleotides, 
resulting in the loss of two highly conserved amino acids [8].  The brindled mutant mouse 
can be rescued by copper treatment provided this occurs before 10 days postnatal [9].  
These mice have been used to investigate the treatment of Menkes disease, however, in 
contrast with the success with the brindled mice, the treatment of human patients with 
copper salts or even with copper histidine has not proven to be very successful, with only a 
handful of successfully treated patients being reported [10].  
The wide range of defects in the mottled mice suggests that Atp7a is involved in 
various aspects of copper physiology in addition to placental transport.  These include 
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uptake of copper across the small intestine and transport of copper across the blood brain 
barrier [11].  The fact that copper accumulates in the kidney of the brindled mouse 
indicates that Atp7a has a role in resorption of copper from the urine.  Copper is absorbed 
into the proximal tubules, but because of the lack of Atp7a, the copper is trapped in cells 
and accumulates in the organ [12].  The Menkes protein is not expressed in hepatocytes 
[13], where the important copper homeostatic mechanism of biliary copper excretion is 
carried out by the closely related protein, ATP7B which is defective in the copper toxicity 
condition, Wilson disease [14].  
To investigate the possibility of gene correction of Menkes disease we report here 
the use of transgenic mice that express the human Menkes protein (ATP7A) to 
demonstrate that the human Menkes gene (ATP7A) allows survival of the brindled mutant, 
the mouse model of Menkes disease.  Despite expression patterns that do not entirely 
match the endogenous gene, the corrected mice are fertile and survive for more than two 
years, but the phenotype of the mutant males corrected with the transgenic line T25#5 
resembled that of the heterozygote females.  
 
2.  Material and methods 
 
2.1.  Animals 
 
All animal studies were approved by Deakin University Animal Welfare 
Committee (A1/1999 and A20/A2001).  Animals were housed under constant conditions 
with a 12 h light and 12 h dark cycle, and given deionised water and standard lab chow 
(Barastoc, Ridley AgriProducts, Australia) ad libitum.  The transgenic mice were 
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maintained in the C57BL/6 background, and the brindled allele of the X-linked mottled 
mutants, Atp7aMo-br in our laboratory is maintained on a C3H/CBA background.  
 
2.3.  Screening of transgenic lines 
 
Mice were genotyped by PCR of tail DNA using the following primer set: sense 
oligonucleotide Y2H7 (5'-TCTCTCTTCCTTAAACTTTAC) corresponding to the 3’ end 
sequence of ATP7A and the antisense oligonucleotide SP6 
(5’-ATTTAGGTGACACTATAG) from the vector.  PCR conditions were: 95ºC for 3 min 
for one cycle, then 30 cycles of: 94ºC for 30 sec, 56ºC for 1 min, 72ºC for 1 min.  Animals 
shown to be transgenic were subsequently mated to wild-type C57BL/6 mice.  Transgenic 
lines were maintained as heterozygotes.  
 
2.4.  Rescue of the brindled males 
 
Transgenic male mice were mated with females carrying the Atp7aMo-br/+ X-linked 
mottled allele.  Pups were screened for presence of the transgene by PCR using the primers 
Y2H7 and SP6 as described previously and the Atp7aMo-br mutation was detected by PCR 
[8].  In brief, sense oligonucleotides MMNK22 (5’-GGCAAAACCTCCGAGGCAAAG) 
specific for the mutant allele or MMNK23 (5’-CAAAACCTCCGAGGCTCTTGC) 
specific for the wild type allele and antisense oligonucleotide MMNK24L 
(5’-AGGAGGAGATTTTCAGAGTTCAG) were used to amplify products of 83 bp and 
87 bp respectively in separate reaction tubes.  PCR conditions were: 96ºC for 4 min, 63ºC 
for 1 min, 72ºC for 1 min for two cycles followed by 96ºC for 1 min, 63ºC for 1 min, 72ºC 
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for 30 sec for 35 cycles.  The products were analysed on 4% agarose 3:1™ HRB gels 
(Amresco, Solon, Ohio, USA) and detected by staining with ethidium bromide.   
 
2.5.  Antibodies 
 
Affinity-purified ATP7A antibody (R17-BX) has been described [15].  Polyclonal 
anti-calnexin antibody (1:500) was purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA).   
 
2.6.  Western blot analysis 
 
Protein extracts were prepared by homogenisation of lung, heart, liver, kidney, 
small intestine, brain and spleen in 140mM Tris-HCl (pH 6.8), 6% SDS, 22.4% glycerol 
and one Mini-EDTA free protease inhibitor tablets (Roche Diagnostics GmbH, Mannheim, 
Germany) per 10 ml of homogenisation buffer.  The protein concentration was determined 
by BCA method (Pierce, Rockford, IL, USA).  Samples containing 40 µg of protein were 
separated using 7.5%SDS/PAGE, transferred to Hybond-C (Amersham Biosciences, 
Bucks, UK) and probed with the R17-BX antibody.  Protein bands were detected by 
donkey anti-sheep/goat horseradish peroxidase-coupled secondary antibody (Chemicon, 
Melbourne, Vic, Australia) using Lumilight Western Blotting Substrate (Roche 
Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions.  
 
2.7.  Immunohistochemical analysis 
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Brain, kidney, heart and lung were immersion-fixed in 4% PFA in PBS for 5 - 24 h 
at 4°C, embedded in paraffin and sectioned at 4 µm on a Microm HM330 microtome 
(Walldorf, Germany).  Small intestine and liver were embedded in OCT compound 
(Tissue-Tek, Sakura Finetek, Torrance, CA, USA) on dry ice and sectioned on a Leica 
CM1850 cryostat (Leica, Nussloch, Germany) at 4 µm.  The sections were air dried for 24 
hours at room temperature and fixed in 4% PFA in PBS.  All tissue sections were treated 
with 3% H2O2 for 10 min to inactivate endogenous peroxidase and blocked in 1% normal 
rabbit serum for 1 h at room temperature.  The sections were then incubated with R17-BX 
antibody diluted 1:2000 in PBS (1:1000 on liver sections) for 1 h at room temperature or 
24 h at 4°C.  Binding of the primary antibody was visualized with the Vectastain ABC Kit 
and Nova Red as the chromogen (Vector Laboratories, Burlingame, CA, USA).  Sections 
were counterstained with Harris’s heamatoxylin (Amber Scientific, Belmont, WA, 
Australia) and mounted with DXT (Chem-Supply, Gillman, SA, Australia).  
 
2.8.  Real time quantitative polymerase chain reaction 
 
Total RNA was isolated using the Qiagen Rneasy Mini Kit according to the 
manufacture’s instructions (Qiagen, Clifton Hill, Vic, Australia).  cDNA was generated 
from 5 µg RNA using StrataScript® reverse transcriptase (Stratagene, East Kew, Vic, 
Australia) following the manufacturer’s instructions.  The specific primers for ATP7A 
were (5’-GCTACCTTGTCAGACACGAATGAG, and 
5’-TCTTGAACTGGTGTCATCCCTTT) and for Atp7a were 
(5’-AAACCTTGCGAGAAGCAATTG, and 5’-GGGCAAAAGAGGTGTTTCCA).  Real 
time PCR was performed in triplicate on 20 ng cDNA (RNA content prior to reverse 
transcription) using the AB 7500 Real Time PCR System (Applied Biosystems, Scoresby, 
Vic, Australia) coupled with SYBR Green technology (Applied Biosystems, Scoresby, 
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Vic, Australia).  The threshold cycle value (Ct), defined as the cycle number when 
fluorescence level exceeds the threshold value was determined using the AB 7500 
software.  The fold change relative to Atp7a in the corrected mutant male was calculated 
using the following equation: 2∆Ct where ∆Ct = mean Ct of endogenous Atp7a  - mean Ct of 
ATP7A.  Values represent mean fold change ± standard deviation.   
 
2.9.  Determination of tissue copper concentration 
 
Tissues were analyzed for trace metals by flame atomic absorption spectrometry, 
using a Varian GTA 100 spectrophotometer (Mulgrave, Vic, Australia).  
 
2.10.  Statistical analysis 
 
All values are expressed as means ± SD, unless otherwise indicated.  Mann-
Whitney tests or Student’s t-tests were used to assess statistical differences between two 
given genotypes.  A P value <0.05 was considered significant.  
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3.  Results 
 
3.1.  Correction of the Menkes defect in the mottled mouse mutant 
 
We used two lines of transgenic mice (T25#5 and T22#2) expressing the human 
Menkes gene to correct the brindled mutants.  The generation and characteristic of the 
lines is described elsewhere [15].  In these lines ATP7A is regulated by the chicken β-actin 
promoter (CAG) and the transgene was found to be widely expressed with some 
differences in expression pattern between the lines.  To introduce the CAG-ATP7A 
transgene into the mutant brindled males, T25#5 or T22#2 transgenic male mice were 
mated with non-transgenic females heterozygous for the Atp7aMo-br X-linked mottled 
allele.  Pups were genotyped by PCR of tail DNA for their transgenic status and for the 
brindled mutation using allele-specific oligonucleotides, as described in Material and 
Methods. Amplification of the mutant allele generated a 83 bp PCR product compared to a 
87 bp fragment from the wild type allele as previously described [8].  Fig. 1A shows the 
PCR results from the four possible Atp7a  genotypes generated from such mating 
(transgene status is not shown).  Out of the total number of 148 pups genotyped at d9 
postnatal, 19 were found to be uncorrected brindled mutants and 18 were found to be 
corrected mutants, the predicted number being 18.5.  The uncorrected mutant males were 
hypopigmented (Fig.2A) and died between 14 and 20 days.  The transgenes permitted 
survival of the mutant but surprisingly the T25#5 corrected mutants (Fig. 2C and D) had a 
mottled coat similar to the heterozygous females (Fig. 2B).  Apart from the mottling of the 
coat of the T25#5 corrected mutant males, corrected mutant males appear in good health 
and have survived for more than 2 years.  Their growth rate was similar to the normal male 
littermates (Fig. 1B) and no significant difference was found between the weight of the 
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corrected mutant males and their normal littermates at d60 postnatal (Student’s t-test).  To 
establish the fertility of the corrected mutant males and demonstrate transmission of the 
mutant allele the corrected males were mated with C57Bl/6 females and pups were 
genotyped as described in Material and Methods.  As expected from X-linked inheritance 
patterns, all female pups were heterozygote for the brindled allele and no brindled males 
were produced.  Out of a total number of 59 progeny, 12 were Atp7aMo-br/+, Tg+; 15 were 
Atp7aMo-br/+, Tg-; 11 were Atp7a+/y, Tg+ and 21 were Atp7a+/y, Tg-.  Most of the work 
described in this paper is on the T25#5 corrected males, as this line was characterized first.  
Subsequently we investigated the correction by a different transgenic line, T22#2.  
Interestingly, T22#2 corrected males had an agouti coat colour similar to their wild type 
littermates (Fig. 2E and F) but otherwise were similar in health, growth rate and longevity 
compared with the T25#5 corrected males.  The corrected mutant males of both lines had 
straight whiskers (note Fig. 2C, D, E and F) contrasting with the curly whiskers of the 
uncorrected mutant (Fig. 2A), which are caused by copper deficiency.  
 
3.2.  Transgene expression in the corrected mutant males 
 
The expression of the ATP7A protein and ATP7A mRNA levels in a range of 
tissues from T25#5 corrected mutant males were determined by Western blot analysis 
(Fig. 3A) using an affinity purified anti-ATP7A antibody R17-BX [15] and real time PCR 
(Fig. 3B).  The R17-BX antibody could detect the mouse Atp7a as well as the human 
protein, however, the sensitivity of the antibody was not sufficient to detect the 
endogenous protein in most tissues of the non-transgenic animals.  Bands at a similar size 
to ATP7A (178Kd) were seen in samples from the lung, kidney, brain and spleen with 
highest levels in kidney (Fig. 3A top panel).  The human protein, ATP7A was expressed in 
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a wide range of tissues of the corrected mutant male, albeit to varying extents and 
migrated in a position consistent with the expected size of 178 kDa (Fig. 3A bottom panel) 
[16].  A strong signal was observed in heart and lower levels of expression were seen in 
small intestine, brain, lung, spleen and kidney.  Expression in the liver was very low, the 
band present at a lower Mr in Fig. 3A is an artifact due to the presence of a major liver 
protein at that position in the gel and is present in both the non-transgenic and transgenic 
livers.  Calnexin, the loading control could not be detected in non-transgenic small 
intestine, most likely due to degradation in this particular sample, since we routinely are 
able to visualize it.  Nevertheless, we have been unable to detect endogenous Atp7a in 
small intestine when the calnexin band is visible.  Since endogenous Atp7a is not detected 
in all tissues tested we could not determine the expression levels of ATP7A relative to the 
endogenous protein.  To estimate the relative levels of transgene expression to the 
endogenous Atp7a gene expression, mRNA levels of Atp7a  and ATP7A were determined 
by real time quantitative PCR (Fig. 3B) on tissue samples from the same corrected mutant 
male presented in Fig. 3A.  ATP7A mRNA expression levels relative to Atp7a  levels were 
markedly increased in heart (244 fold), small intestine (38 fold), brain (11 fold), lung (7 
fold), kidney (3 fold) and spleen (2 fold).  Lower expression levels were measured in liver 
(1.7 fold) consistent with the Western blot results.  
The cellular distribution of ATP7A in various organs was determined by 
immunohistochemistry using the R17-BX antibody.  Endogenous Atp7a was undetectable   
in non-transgenic mice under the conditions used (data not shown). The transgene was 
expressed in a mosaic pattern in most tissues examined (Fig. 4).  In the lung ATP7A was 
detected in smooth muscle of pulmonary vessels, but not in the parenchyma (Fig. 4A).  In 
the heart the transgene was expressed in cardiac muscle (Fig. 4B).  In the liver, we found 
expression of the transgene in clusters of hepatocytes (Fig. 4C), however, the majority of 
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hepatocytes did not appear to express ATP7A.  Interestingly the protein appeared to be at 
the plasma membrane rather than in an intracellular location as was seen in most other cell 
types. In the small intestine the transgene was expressed in the perinuclear region on the 
apical side of the enterocytes (Fig. 4D) consistent with the TGN localization in these cells 
reported by Monty et al [17].  In kidney the transgene was expressed in the macular densa 
of the distal tubules (Fig. 4E), in tubules in the outer cortex (Fig. 4F), as well as in the thin 
loops of Henle in the outer medulla (data not shown).  In the brain, we found transgene 
expression in the Purkinje cell layer of the cerebellum (Fig. 4G), in the CA1 and CA2 
region of the hippocampus (Fig. 4H), the mitral layer of olfactory bulb and in some 
instances in the vascular endothelium (data not shown).  Some expression was detected in 
the choroid plexus but we could not detect expression in astrocytes (data not shown).  
 
3.3.  Effect of ATP7A expression on Cu concentration in corrected mice 
 
Copper concentrations in the mice were determined at 12 days (Table 1) and 60 
days postnatal (Table 2).   Copper concentrations in the heart of the uncorrected mutant 
male at 12 days of age were much lower than normal (8.8 ± 2.1 µg/g v 24.1 ± 9.7 µg/g) but 
the copper concentrations were restored to normal levels in the heart of the corrected 
mutants.  In the liver the normal males and female had high copper concentrations 
typically found in mice prior to weaning [18].  The uncorrected male mutant and the 
heterozygous females both had very low copper concentrations in their livers.  The 
presence of the transgene in the male mutants increased the hepatic copper concentrations 
by about 50%, still well below the normal values.  Interestingly the expression of ATP7A 
in the heterozygous females caused a marked increase (250%) in hepatic copper 
concentrations but not to the levels found in normal animals.  Both the heterozygous 
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female and the mutant male had very high copper concentrations in the kidney.  The 
expression of the transgene decreased the kidney copper concentrations in the 
heterozygous female, but increased the copper in the kidneys of the corrected males.  
Although ATP7A was well expressed in the small intestine (Fig. 4B), this did not appear 
to correct the elevation of copper in the small intestine of the mutant male or heterozygous 
female.  The brain of the uncorrected mutant had extremely low copper concentrations (3.3 
± 0.1 µg/g v 8.9 ± 1.4 µg/g in normal mice), this severe copper deficiency was completely 
corrected by the expression of the transgene.   
Copper concentrations in the tissues of the 60 day-old animals is shown in Table 2.   
The uncorrected mutant males had all died by this age.  Copper concentrations in the 
corrected mutants heart and liver were normal.  In the kidney of the corrected males the 
copper concentrations were almost 6 fold higher than the normal males, and were similar 
to the values seen in the heterozygous females expressing the transgene; the 
non-transgenic heterozygous females, however, had renal copper concentrations 
approximately 9 fold higher than normal females.  The small intestine copper levels were 
slightly elevated in the corrected mutant males, and again resembled the values seen in the 
heterozygous females.  By this age the brain copper concentrations of all genotypes was 
similar.   
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4.  Discussion 
 
The expression of the human Menkes protein permitted survival of the brindled 
mutant males, however, the copper concentrations were not restored to those found in the 
normal male but were similar to copper concentrations in the heterozygous females.  As 
we found here and previously reported [19, 20], the females heterozygous for the 
Atp7aMo-br allele have quite abnormal copper concentrations with pronounced copper 
accumulation in the small intestine, kidney and low copper concentrations in the liver 
similar to the values seen in the mutant male, yet the females survive normally.  The 
explanation for the copper accumulation is that, as a result of random X-inactivation, 
approximately 50% of cells in each tissue are expressing the mutant allele and accumulate 
copper due to defective efflux. As with cells from patients with Menkes disease, the 
mutant cells take up copper but cannot efflux it, leading to accumulation [21].  The 
intestinal enterocytes expressing the normal allele of Atp7a transport copper into the body, 
clearly allowing sufficient copper to reach critical enzymes to permit normal growth and 
development.  The low levels of copper in the liver are an indication that supplies of 
copper are limited, probably due to a combination of the reduced intestinal transport (only 
50% of cells operating transporting copper), and a “copper sink” effect of cells expressing 
the mutant allele accumulating copper.  Thus the heterozygous female is a genetic mosaic 
of cells in which copper is normally handled and cells in which copper is accumulating, 
but is not transported across the transGolgi network to cuproenzymes in the secretory 
pathway.  This mosaicism manifests as a mottled coat; the normally pigmented cells have 
an active tyrosinase that receives copper from Atp7a, and the hypopigmented patches 
represent cells containing an inactive tyrosinase due to the mutant Atp7a.  
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Our data suggests that, like the heterozygous female, the males corrected with the 
T25#5 transgene are a genetic mosaic of transgene-expressing or non-expressing cells (eg 
Fig. 4).  The consequences for coat colour and tissue copper accumulation are similar to 
that seen in the heterozygous females, however, the exact phenotype will depend on the 
pattern of transgene inactivation, which is likely to vary between lines of mice and 
possibly even between individuals of the same line.  The observation that the corrected 
males of the T22#2 line have a normal coat suggests that the transgene in this line is 
uniformly expressed in the skin, but other data has shown mosaic expression in other 
tissues [15].  Mosaic expression of transgenes is not uncommon and presumably reflects 
random silencing events as was shown for the keratin 5/lacZ constructs which express in a 
mosaic fashion in the epithelium of transgenic mice [22] and may be a consequence of the 
chromosomal integration site or transgene copy number [23].  We have not investigated 
the site of integration of the transgene or the copy number in transgenic lines T25#5 and 
T22#2, however, PCR screening for presence of the transgene suggests that the copy 
number of the T22#2 line is higher than that of the T25#5 line (not shown).  Variable 
transgene expression has been reported for a number of genes regulated by the CAG 
promoter [24-26]. Although this property could potentially be an issue if one is 
considering gene correction for Menkes disease, our results demonstrate that even partial 
correction is sufficient to achieve normal growth and development.     
ATP7A expression and ATP7A mRNA levels were found to vary widely between 
the tissues of the corrected mutant mice.  Expression was highest in the heart muscle cells 
where the levels were over two hundred times relative to the endogenous mRNA.  In cells 
where the endogenous protein was detectable, such as the kidney, relative levels were 
about 3 fold higher than the endogenous gene.  The high relative expression in the heart is 
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due to a combination of the high activity of the CAG promoter in muscle cells [26] and the 
very low endogenous levels in this tissue.   
The over-expression of ATP7A did not result in apparently abnormal intracellular 
distribution of the protein as it was found in regions consistent with the transGolgi 
network, the established location of the Menkes protein in a normal copper environment 
[27].  Elevated levels of ATP7A in cells has shown to cause depletion of copper, due to 
enhanced efflux of copper [28, 29], and this effect is apparent in the trend for reduced 
copper concentrations in the hearts of the transgenic animals (Table 2) [15].  It has not 
been established whether this copper depletion has any physiological consequences for the 
heart.  
ATP7A was expressed in patches of hepatocytes in the liver of the corrected mice, 
and unlike other cell types appeared located on the plasma membrane, rather than in a 
region consistent with the TGN.  It is probably that this region is the basolateral surface of 
the hepatocyte, as ATP7A has been shown to traffic to the basolateral surface in polarized 
cells [30] and proteins that are located on the apical surface of hepatocytes give a 
characteristic discrete circular staining pattern [31, 32].  Normally hepatocytes do not 
express ATP7A, instead they express the closely related Wilson protein, ATP7B [31].  
When the copper levels in the hepatocyte are low, ATP7B is found in the TGN, but the 
protein traffics to large vesicles in the vicinity of the biliary canalicular membrane when 
the copper levels are elevated leading to biliary excretion of copper [31].  Our result 
suggests a physiological reason for the lack of ATP7A expression in the liver in normal 
animals.  If ATP7A were normally expressed in hepatocytes it would presumably pump 
copper into the sinusoidal space, and hence back into the circulation, rather than delivering 
excess copper into the bile and act in opposition to the biliary excretion role of ATP7B.  It 
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will be of interest to explore further the physiological consequences of this presumed 
reversal of copper flow in further experiments.  
Although the pattern of expression of the transgene in tissues did not precisely 
match that of the reported expression patterns of the endogenous gene [12], ATP7A was 
expressed in the tissues critically important for the survival of the mutant mice.  For 
example, ATP7A was well expressed in the intestinal enterocytes where copper 
accumulates in mutants when the Menkes protein is defective [19], and this expression 
presumably allows the absorption of dietary copper.  Recently Monty et al. have shown 
that ATP7A in the intestinal enterocytes of the ATP7A transgenic mice responded to 
increasing copper in the lumen of the small intestine by trafficking from a perinuclear 
region to vesicles in the basolateral region, presumably facilitating copper delivery to the 
circulation [17].  The fact that the brain copper is restored to normal is of critical 
importance for the survival of the mice.  The Menkes protein is thought to be necessary for 
the transport of copper across the blood brain barrier, and in mutant mice copper has been 
found to accumulate in the vascular endothelium and astroglial cells of the mouse brain 
[33].  Surprisingly we could not detect consistent expression of the transgene in the 
vascular endothelial cells or astrocytes, nevertheless we suggest that a low but 
undetectable amount of ATP7A must have been present, otherwise copper would not have 
been able to reach the brain.  We note that our antibodies are not sensitive enough to detect 
endogenous levels of Atp7a, so expression of the transgene at levels equivalent to the 
normal protein may not have been visible in the sections. We detected substantial amounts 
of ATP7A in the Purkinje cell layer of the cerebellum, in the CA1 and CA2 region of the 
hippocampus and in the mitral layer of olfactory bulb, which are also reported to express 
the Atp7a in normal mice [12, 34].  This expression of the transgene may have assisted in 
the restoration of normal brain function, however, the complete role of the Menkes protein 
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and indeed copper in the brain is far from clear.  
In Menkes patients copper accumulates in the proximal tubules of the kidney, the 
place of copper resorption [11].  We found ATP7A expression in the macular densa of the 
distal tubules, in tubules in the outer cortex, as well as in the thin loops of Henle in the 
outer medulla, which was sufficient to reduce the copper levels of the corrected mutant 
males compared to the heterozygote females.  Comparison of transgene expression with 
the endogenous Atp7a is complicated by the differences in published reports of the 
expression pattern of Atp7a in the kidney.  For example, strong endogenous Atp7a 
expression was found by in situ hybridization studies in the proximal tubules, however low 
levels of expression were found in the glomeruli [35].  Moore and Cox found strong 
endogenous expression in the glomeruli using in situ hybridization and slight expression in 
the interior of various tubules [36].  We have previously detected Atp7a in both the 
proximal and distal convoluted tubules with little staining in the glomeruli [8].  
Normally the livers of fetal mice accumulate copper far above the adult levels, and 
the high concentrations are maintained throughout the first 10-15 days of life [18].  The 
uncorrected mutant has an extremely low hepatic copper concentration of 10.7 ± 2.4 µg/g 
at 12 days compared with the normal male littermate (164.5 ± 70.6 µg/g), consistent with 
the severe copper deficiency of the mutants.  This low liver copper is primarily due to the 
defective transport of copper across the mutant placenta [7].  The transgene only partially 
corrects this deficiency, with the hepatic copper being only 15.8 ± 4.5 µg/g.  This value 
suggests that the expression of the transgene must be moderately restricted in the placenta 
but we have not assessed placental expression.  Interestingly the 12 day-old heterozygous 
females have low hepatic copper as well (14.9 ± 3.6 µg/g) which may be due to the 
preferential inactivation of the normal paternal allele in the placenta leaving most of the 
fetal placenta with the mutant X active [37].  The transgene in the heterozygous females 
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increases hepatic copper concentrations of around 50 µg/g closer to the normal values than 
the corrected mutant males.  It is probable that the expression of the transgene in the 
placenta supplements the restricted placental copper transport by increasing the number of 
placental trophoblasts expressing an active Menkes protein.  Despite the low hepatic 
copper concentrations in the corrected mutant males and heterozygous females the pups 
develop normally.  
In conclusion the rescue of the brindled mutants demonstrates that even partial 
correction of the Menkes genetic defect in humans would be sufficient for relatively 
normal development and these mice also will provide further information about the role of 
the Menkes ATPase in copper physiology.  
 20 
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Figure legends 
 
Fig. 1.  Characterization of the corrected mutant mice.  (A) PCR detection of the brindled 
mutation in tail DNA from the progeny of transgenic male mice mated with non-transgenic 
females heterozygous for the Atp7aMo-br X-linked mottled allele.  Primers MMNK22 and 
MMNK24L detect the mutant allele (M) and primers MMNK23 and MMNK24L detect 
the wild type allele (W).  (B) Growth curves of corrected mutant and normal male mice.  
Measurements represent the average weight of three corrected mutant mice (dashed line) 
and two normal male littermates (solid line).  Error bars indicate standard deviation.   
 
Fig. 2.  Appearance of corrected mutant mice.  (A) Uncorrected mutant mouse at 12 days 
of age.  (B) Heterozygote female. (C) T25#5 corrected mutant male mouse at 105 days of 
age. (D) Another T25#5 corrected mutant male mouse at 78 days of age (left) compared to 
a normal male littermate (right).  (E) T22#2 corrected mutant male mouse at 186 days of 
age.  (F) Another T22#2 corrected mutant male mouse at 135 days of age (left) compared 
to a normal male littermate (right).   
 
Fig. 3.  Transgene expression in mouse tissues.  (A) Representative Western blots of 40 µg 
protein extracts from a normal male, Tg- (top panel) and a corrected mutant male (bottom 
panel) mouse tissues. The R17-BX antibody detected ATP7A (178 kDa) in lung, heart, 
spleen, kidney, small intestine (SI), and brain of the corrected mutant male.  Endogenous 
Atp7a was detected in lung, kidney, brain and spleen.  Calnexin was used as a loading 
control and detected using a polyclonal antibody.  (B) Gene expression of ATP7A in the 
same corrected mutant male analysed by Western blot.  mRNA levels were expressed 
relative to endogenous Atp7a.  Real time quantitative PCR data for normal male (open 
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bars) and corrected mutant male (dotted bars) represent mean fold change ± standard 
deviation in the logarithmic scale.   
 
Fig. 4.  Immunohistochemical analysis of ATP7A in various tissues of a representative 
corrected mutant male mouse collected at 60 days postnatal.  Tissue sections were 
prepared as described in Material and Methods, and ATP7A was detected with the 
R17-BX antibody and immunoperoxidase staining.  Endogenous Atp7a was not detected 
(data not shown).  ATP7A expression was detected in lung (A), heart (B), liver (C), SI 
(small intestine) (D), kidney (E and F), the Purkinje cell layer of the cerebellum (G) and in 
the CA2 region of the hippocampus (H).  Arrows indicate a typical cell expressing 
ATP7A.  In panels B, E and F there is some background staining due to longer 
development time for those sections.  Bar = 50 µm. 
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Table 1.  
Tissue copper concentration in organs of 12 day-old progeny generated from the mating of transgenic male and Atp7aMo-br female mice.    
   Cu µg/g dry weight of mice tissue 
Tg & description Coat colour Genotype Heart Liver Kidney SI Brain 
Normal female (-) Ag  Tg- Atp7a+/+ 17.2 ± 6.6 (6) 222 ± 81.4 (8) 16.9 ± 7.0 (5) 20.8 ± 8.0 (7) 11.1 ± 3.0 (7) 
Normal female (+) Ag Tg+ Atp7a+/+ 18.0 ± 4.0 (4) 164.8 ± 92.2 (6) 10.0 ± 1.3 (4) 20.9 ± 6.9 (5) 8.5 ± 1.4 (6) 
Heterozygote female (-) Br  Tg- Atp7aMo-br/+ 20.4 ± 9.1 (6) 14.9 ± 3.6 (6) 88.2 ± 7.7 (5) 35.5 ± 3.6 (5) 5.9 ± 1.4 (6) 
Heterozygote female (+) Ag or Br Tg+ Atp7aMo-br/+ 13.4 ± 5.8 (6) 52.8 ± 13.6 (5) d 71.2 ± 5.8 d 48.8 ± 18.6 (5) d 7.8 ± 2.4 (5) 
Normal male (-) Ag  Tg- Atp7a+/y 24.1 ± 9.7 (5) 164.5 ± 52.4 (6) 18.5 ± 8.1 (5) 24.4 ± 6.9 (6) 8.9 ± 1.4 (5) 
Normal male (+) Ag  Tg+ Atp7a+/y 17.1 ± 4.6 (4) 164 ± 70.6 (5) 19.3 ± 5.1 (4) 14.9 ± 2.7 (5) 10.9 ± 2.8 (5) 
Uncorrected mutant (-) Wh  Tg- Atp7aMo-br/y 8.8 ± 2.1 (4) 10.7 ± 2.4 (7) 52.2 ± 10.3 (6) 59.2 ± 43.2 (7) 3.3 ± 0.1 (5) 
Corrected mutant (+) Br Tg+ Atp7aMo-br/y 21.5 ± 8.2 (3) b 15.8 ± 4.5 (4) a 66.0 ± 15.6 (4) a, c 54.9 ± 27.4 (4) a 9.3 ± 3.5 (4) b 
 
Results are copper concentration expressed as µg/g dry weight of tissue ± standard deviation, number of observations in parentheses.  SI, small intestine. Ag = normal agouti 
coat, Br = mottled brindled coat, Wh = white coat. Tg- and Tg+ refer to non-transgenic and transgenic mice, respectively.  P<0.05 were found for the following pairs:  
a Corrected mutant (+) versus normal male (+),  
b Corrected mutant (+) versus uncorrected mutant (-),  
c Corrected mutant (+) versus heterozygote female (-),  
d Heterozygote female (+) versus normal femle (+).    
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Table 2.  
Tissue copper concentration in 60 day-old progeny generated from the mating of transgenic male and Atp7aMo-br female mice. 
   Cu µg/g dry weight of mice tissue 
Tg & description Coat colour Genotype Heart Liver Kidney SI Brain 
Normal female (-) Ag  Tg- Atp7a+/+ 19.3 ± 2.2 (5) 15.6 ± 2.1 (4) 17.9 ± 1.5 (5) 8.2  ± 2.3 (5) 15.0 ± 1.1 (5) 
Normal female (+) Ag Tg+ Atp7a+/+ 17.1 ± 2.6 (4) 13.5 ± 1.5 (4) 15.1 ± 1.4 (4) 9.7 ± 1.5 (4) 14.6 ± 1.4 (4) 
Heterozygote female (-) Br  Tg- Atp7aMo-br/+ 22.1 ± 5.0 (5) 14.1 ± 1.8 (5) 137.0 ± 44.3 (4) 15.7 ± 2.8 (5) 11.3 ± 3.2 (5) 
Heterozygote female (+) Ag or Br Tg+ Atp7aMo-br/+ 17.1 ± 3.0 (4) 14.7± 3.9 (5) 82.6 ± 14.1 (5) c 14.4 ± 1.2 (5) c 15.9 ± 1.0 (5) 
Normal male (-) Ag  Tg- Atp7a+/y 18.5 ± 2.0 (5) 19.2 ± 2.7 (5) 17.1 ± 2.2 (5) 9.6 ± 1.5 (5) 13.4 ± 1.1 (5) 
Normal male (+) Ag  Tg+ Atp7a+/y 13.8 ± 2.3 (7) 18.4 ± 2.5 (6) 14.6 ± 3.1 (7) 9.0 ± 0.9 (7) 15.0 ± 1.4 (7) 
Corrected mutant (+) Br Tg+ Atp7aMo-br/y 15.5 ± 2.9 (5) b 17.7 ± 1.7 (6) b 84.6 ± 4.9 (6) a, b 15.6 ± 2.5 (6) a 15.3 ± 1.9 (6) 
 
Results are copper concentration expressed as µg/g dry weight of tissue ± standard deviation, number of observations in parentheses.  SI, small intestine. Ag = normal agouti 
coat, Br = mottled brindled coat. No data are listed for the uncorrected mutants (-) because they all d ied around 14-20 days of age.  P<0.05 were found for the fo llowing pairs:  
a Corrected mutant (+) versus normal male  (+),  
b Corrected mutant (+) versus heterozygote female (-),   
c Heterozygote female (+) versus normal female (+).   
 
 
Figure 1
Click here to download high resolution image
Figure 2
Click here to download high resolution image
Figure 3
Click here to download high resolution image
Figure 4
Click here to download high resolution image
